| clinical consequences for the PM |
|---|
| increased risk of toxicity |
| debrisoquine |
postural hypotension and physical collapse |
| sparteine |
oxytocic effects |
| perphenazine |
extrapyramidal symptoms |
| flecainide |
possibly ventricular tachyarrhythmias |
| perhexiline |
neuropathy and hepatotoxicity |
| phenformin |
lactic acidosis |
| propafenone |
CNS toxicity and bronchoconstriction |
| metoprolol |
loss of cardioselectivity |
| nortriptyline |
hypotension and confusion |
| terikalant |
excessive prolongation in QT interval |
| dexfenfluramine |
nausea, vomiting and headache |
|
l-tryptophan |
eosinophilia-myalgia syndrome |
| indoramin |
sedation |
| thioridazine |
excessive prolongation in QT interval |
| tramadol |
hyper-anticoagulation from warfarin |
| failure to respond |
|
| codeine |
poor analgesic efficacy |
| tramadol |
poor analgesic efficacy |
| opiates |
protection from oral opiate dependence |
